Lian I. Liu
No. 107, Wenhua West Road
Jinan, 250012, China
Jinan, 250012, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 26, 2026
Optimal First-line Immune-related Therapy Selection for Advanced Gastric Cancer: A Systematic Review and Network Meta-analysis.
Journal: Journal of gastrointestinal cancer
Published: April 04, 2026
Global burden and inequality of childhood kidney cancer (1990-2050): a systematic analysis for the global burden of disease study 2021.
Journal: World journal of urology
Published: March 23, 2026
Predicting Intratumoral Heterogeneity and Stratifying Prognostic Risk in Gastric Cancer Using a Histology-Based Pathomics-Deep Learning Fusion Model.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: January 28, 2026
Individualized blood pressure management and postoperative organ dysfunction in older hip fracture patients: a study protocol for a single-center, randomized, controlled trial.
Journal: BMC geriatrics
Published: November 27, 2025
Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.
Journal: Frontiers in immunology
Published: November 25, 2025
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: April 23, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.
Journal: The lancet. Gastroenterology & hepatology
Published: April 03, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
Journal: Cancer communications (London, England)
Published: March 24, 2025
The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy.
Journal: Critical reviews in oncology/hematology
Published: March 18, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 18, 2025
Last Updated: 09/26/2026